Fulcrum Therapeutics Stock Price, News & Analysis

Fulcrum Therapeutics (Nasdaq: FULC) will participate in a virtual fireside chat at the 2022 BofA Securities Biotech SMID Cap Conference on December 8, 2022, at 9:10 a.m. ET. The event aims to provide insights into the company's initiatives focused on genetically defined rare diseases. A live audio webcast will be accessible on the Fulcrum website, with an archived replay available for 30 days after the event. Fulcrum is advancing two key clinical programs: losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease.

Fulcrum Therapeutics (Nasdaq: FULC) announced the granting of non-statutory stock options totaling 478,820 shares to four new employees, including 400,000 shares to Santiago Arroyo, M.D., Ph.D., the new Chief Medical Officer. The options, priced at $5.61 per share, are part of the 2022 Inducement Stock Incentive Plan and include a ten-year term with vesting over four years. Fulcrum is dedicated to addressing genetically defined rare diseases, focusing on advancing its lead drugs for facioscapulohumeral muscular dystrophy and sickle cell disease.

Fulcrum Therapeutics (NASDAQ: FULC) reported Q3 2022 results, maintaining a focus on clinical and operational progress. Key highlights include the selection of a 12mg dose for the Phase 1b trial of FTX-6058 for sickle cell disease (SCD) and positive 96-week data from the Phase 2 ReDUX4 trial of losmapimod. The equity raise yielded approximately $80.8 million, extending their cash runway into late 2024. The firm anticipates two registration-enabling trials in the next 18 months, with a Q3 net loss of $23.7 million, up from $20.7 million in Q3 2021.

Fulcrum Therapeutics (NASDAQ: FULC) enhances its leadership with the appointment of Santiago Arroyo, M.D., Ph.D., as Chief Medical Officer and Jeff W. Jacobs, Ph.D., as Chief Scientific Officer. Dr. Arroyo, with nearly 20 years in biopharmaceuticals, previously led clinical developments at Momenta Pharmaceuticals. Dr. Jacobs brings over 25 years of drug discovery experience, most recently at Goldfinch Bio. Both executives aim to advance Fulcrum's clinical programs, including therapies for facioscapulohumeral muscular dystrophy (FSHD) and sickle cell disease, by leveraging their extensive expertise.

Fulcrum Therapeutics (Nasdaq: FULC) announced its third-quarter 2022 financial results will be released on November 8, 2022, before U.S. markets open. Management plans to host a conference call at 8:00 a.m. ET to discuss the results and recent corporate developments. The company focuses on improving lives in genetically defined rare diseases and has ongoing clinical programs for losmapimod for FSHD and FTX-6058 for sickle cell disease. Interested parties can access the call through the Investor Relations section of the company's website.

Fulcrum Therapeutics (NASDAQ: FULC) announced its participation in two upcoming investor conferences. The first is the Credit Suisse 31st Annual Healthcare Conference on November 8, 2022, at 2:35 p.m. PT, featuring a fireside chat. The second is the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 4:30 p.m. ET, also including a fireside chat. Interested investors can listen to live webcasts through the Investor Relations section of Fulcrum's website, with archived replays available for 30 days.

Fulcrum Therapeutics announced promising data from the open-label extension of its Phase 2 ReDUX4 trial of losmapimod for treating facioscapulohumeral muscular dystrophy (FSHD). Findings suggest losmapimod modifies disease progression, with 97% of participants on treatment at 96 weeks demonstrating improved muscle function. The trial showcased a favorable safety profile, with no serious adverse events. The results will be presented at the World Muscle Society Congress on October 12, 2022, reinforcing the potential of losmapimod as a first approved treatment for FSHD.

Fulcrum Therapeutics (Nasdaq: FULC) announced the granting of stock options for 6,180 shares to a new employee as inducement awards under its 2022 Inducement Stock Incentive Plan. The options, issued on October 3, 2022, have an exercise price of $8.16 per share, equal to the closing stock price on that date. These options will vest over four years, with a quarter vesting after the first year and the remainder in quarterly installments. Fulcrum focuses on developing treatments for genetically defined rare diseases with significant unmet medical needs.

Fulcrum Therapeutics (NASDAQ: FULC) announced the granting of 59,500 non-statutory stock options to three new employees on September 6, 2022. These options serve as inducement awards outside the 2019 Stock Incentive Plan. The exercise price is set at $7.47 per share, corresponding to the closing price on the grant date. Each option has a ten-year term with a four-year vesting period, allowing 25% to vest after the first year and the remainder in quarterly installments. Fulcrum focuses on developing treatments for genetically defined rare diseases.